Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
European Urology Focus|May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate CancerEdmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 11, 2024
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&TJames P Buteau, Louise Kostos, Ramin Alipour, et al.
Clinical Genitourinary Cancer|April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world StudyJ Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
European Urology|June 4, 2020
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate CancerHeidi Fettke, Edmond M Kwan, Maria M Docanto, et al.
JCO Precision Oncology|July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate CancerEdmond M Kwan, Chao Dai, Heidi Fettke, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
European Urology Focus|May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate CancerEdmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 11, 2024
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&TJames P Buteau, Louise Kostos, Ramin Alipour, et al.
Clinical Genitourinary Cancer|April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world StudyJ Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
European Urology|June 4, 2020
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate CancerHeidi Fettke, Edmond M Kwan, Maria M Docanto, et al.
JCO Precision Oncology|July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate CancerEdmond M Kwan, Chao Dai, Heidi Fettke, et al.
Pageof 14